Overview

Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid Leukemia

Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
This study is designed to test the combination of decitabine, arsenic trioxide and ascorbic acid in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia
Phase:
Phase 1
Details
Lead Sponsor:
Washington University School of Medicine
Collaborator:
Cephalon
Treatments:
Arsenic Trioxide
Ascorbic Acid
Azacitidine
Decitabine